Pioglitazone in nonalcoholic steatohepatitis [1]

New England Journal of Medicine

Volumn 356, Issue 10, 2007, Pages 1067-1069

  Targher, Giovanni ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LETTER; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; TREATMENT RESPONSE; FATTY LIVER; GLUCOSE INTOLERANCE; HOSPITALIZATION; LIVER; NOTE; PATHOLOGY; KINESIOTHERAPY; LOW CALORY DIET; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; DIET, REDUCING; EXERCISE THERAPY; WEIGHT LOSS;

EID: 33847706491     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc063685     Document Type: Letter

References (4)

1. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
3. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40:Suppl 1:S17-S29.
4. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421-7.